Parag Kumthekar

Gene Therapy Downstream Process Development Lead at UCB Pharma

Speaker

Parag leads the AAV-based gene therapy downstream process development team at UCB, driving early-phase programs from development through toxicology studies and full CMC readiness. He collaborates closely with research, analytics, regulatory, quality, formulation, and drug product teams to ensure seamless progress.

With over 15 years of industrial experience, Parag specializes in downstream bioprocess development across diverse modalities, including AAV viral vectors, monoclonal antibodies and fragments, peptides, fusion proteins, PEGylated proteins recombinant proteins and Insulins. His core strengths lie in chromatography, filtration, lyophilization, scale-up, and tech transfer.r